Arrowhead Pharmaceuticals (STU:HDP1) 3-Year Revenue Growth Rate : 37.20% (As of Dec. 2023)

View and export this data going back to 1997. Start your Free Trial

What is Arrowhead Pharmaceuticals 3-Year Revenue Growth Rate?

Arrowhead Pharmaceuticals's Revenue per Share for the three months ended in Dec. 2023 was €0.03.

During the past 12 months, Arrowhead Pharmaceuticals's average Revenue per Share Growth Rate was -35.30% per year. During the past 3 years, the average Revenue per Share Growth Rate was 37.20% per year. During the past 5 years, the average Revenue per Share Growth Rate was 47.50% per year. During the past 10 years, the average Revenue per Share Growth Rate was 107.10% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Revenue per Share growth rate.

During the past 13 years, the highest 3-Year average Revenue per Share Growth Rate of Arrowhead Pharmaceuticals was 729.50% per year. The lowest was -75.00% per year. And the median was 4.10% per year.

Competitive Comparison of Arrowhead Pharmaceuticals's 3-Year Revenue Growth Rate

For the Biotechnology subindustry, Arrowhead Pharmaceuticals's 3-Year Revenue Growth Rate, along with its competitors' market caps and 3-Year Revenue Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Arrowhead Pharmaceuticals's 3-Year Revenue Growth Rate Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Arrowhead Pharmaceuticals's 3-Year Revenue Growth Rate distribution charts can be found below:

* The bar in red indicates where Arrowhead Pharmaceuticals's 3-Year Revenue Growth Rate falls into.

Arrowhead Pharmaceuticals 3-Year Revenue Growth Rate Calculation

This is the 3-year average growth rate of Revenue per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Revenue per Share growth rate.

Arrowhead Pharmaceuticals (STU:HDP1) 3-Year Revenue Growth Rate Explanation

Revenue per Share is the amount of Revenue per outstanding share of the company's stock.

Revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top. Revenue per share growth rate is used in calculating Predictability Rank, companies with more consistent revenue and earnings growth are ranked high with predictability.

Arrowhead Pharmaceuticals 3-Year Revenue Growth Rate Related Terms

Thank you for viewing the detailed overview of Arrowhead Pharmaceuticals's 3-Year Revenue Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

Arrowhead Pharmaceuticals (STU:HDP1) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Arrowhead Pharmaceuticals Inc (STU:HDP1) » Definitions » 3-Year Revenue Growth Rate

Comparable Companies

Traded in Other Exchanges

ARWR:USA

Address

177 E. Colorado Boulevard, Suite 700, Pasadena, CA, USA, 91105

Website

https://www.arrowheadpharma.com

Arrowhead Pharmaceuticals Inc is an American biotechnology company. Its main target is the development of medicine to treat diseases with a genetic origin, characterized by the overproduction of one or more proteins. Its medical solutions are aimed at the genes that trigger the diseases. Its portfolio includes drugs targeting hepatitis B, Alpha-1 Antitrypsin Deficiency, thrombosis and angioedema, clear-cell and renal cell carcinoma, and cardiovascular disease.

Arrowhead Pharmaceuticals (STU:HDP1) Headlines

No Headlines